Effects of Amino Acids on Regional Lipid Metabolism (NH)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by University of Arkansas
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
NCT01150188
First received: June 22, 2010
Last updated: December 18, 2014
Last verified: December 2014

June 22, 2010
December 18, 2014
June 2010
June 2015   (final data collection date for primary outcome measure)
Very low density lipoprotein (VLDL) turnover [ Time Frame: Eight weeks ] [ Designated as safety issue: No ]
Turnover rates of VLDL-triglycerides and VLDL-ApoB-100, including synthesis and breakdown rates, measured before and after eight weeks of amino acid supplementation
Same as current
Complete list of historical versions of study NCT01150188 on ClinicalTrials.gov Archive Site
  • Fat oxidation [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Fat oxidation measured before and after eight weeks of amino acid supplementation
  • Lipolysis [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Lipolysis measured before and after eight weeks of amino acid supplementation
  • Triglyceride uptake in muscle and adipose tissue [ Time Frame: Eight weeks ] [ Designated as safety issue: No ]
    Triglyceride uptake in muscle and adipose tissue measured before and after eight weeks of amino acid supplementation
Same as current
Not Provided
Not Provided
 
Effects of Amino Acids on Regional Lipid Metabolism
Effects of Amino Acids on Regional Lipid Metabolism

Elevated fat level in blood is a risk factor for coronary heart disease, a major cause of death in America. The overall goal of this project is to test a novel treatment using nutrient (amino acid) supplementation against this condition in men and women, and to understand how this treatment works.

Coronary heart disease (CHD) remains the single largest killer of American men and women (45). Hyper¬triglyceridemia (elevated triglyceride [TG] concentration in the blood) has been shown to be a significant independent risk factor for CHD (7;8;25), accordingly, treatment for hypertriglyceridemia has been included in the Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (36). In a meta-analysis of 21 population-based prospective studies including a total of 65,863 men and 11,089 women, each increase of 89 mg/dl (1 mmol/l) in TG concentration was associated with a 32% increase in CHD risk in men and 76% increase in women (3). Thus, hypertriglyceridemia is an even stronger risk factor for CHD in women than in men.

The prevalence of hypertriglyceridemia is high. It is a common finding with aging, and is also associated with overweight, obesity, diabetes, and renal disease (39). With the aging of the US population and ongoing epidemics of obesity and type 2-diabetes, the number of individuals with conditions associated with elevated TG levels is likely to grow.

4.1.2 Effect of Amino Acids on Plasma Triglyceride Concentration In an effort to clarify the potential independent effect of protein on plasma and tissue lipids, we supplemented a normal weight-maintaining diet with a relatively small amount of amino acids (~90 kcal/day) between meals. We measured tissue lipids in addition to plasma lipids since the increase in insulin resistance with aging has been linked to increased fat accumulation in muscle and liver tissue (20;63). Also, it has repeatedly been shown that amino acid intake stimulates muscle protein synthesis and improves muscle protein net balance (86). Our hypothesis was that supplementation of the normal diet with a mixture of amino acids will reduce circulating and tissue TG concentrations and improve insulin sensitivity in elderly subjects with impaired glucose tolerance. Twelve impaired glucose tolerant elderly ingested 11 g of essential amino acids (EAA) + arginine twice a day for 16 weeks, after a 7 week control run in. Diet and activity were not otherwise modified. We found individuals consuming the EAA supplement had improved physical function. Further, these individuals had lower plasma and liver TG concentrations than before supplementation, and total cholesterol and VLDL-cholesterol concentrations were also lower after supplementations (12). In the present study, we will investigate this by supplementing the diet of older subjects shown to have hypertriglyceridemia.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Hypertriglyceridemia
  • Dietary Supplement: Amino acids
    11 g amino acids two times per day for eight weeks
  • Dietary Supplement: Placebo
    Placebo of inert compounds, 11 g two times per day for eight weeks
  • Active Comparator: Amino acids
    Amino acid supplementation between meals for eight weeks
    Intervention: Dietary Supplement: Amino acids
  • Placebo Comparator: Placebo
    Supplementation of placebo (inert components) between meals for eight weeks
    Intervention: Dietary Supplement: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
December 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 50-75 years.
  • Men and Women (Women postmenopausal).
  • Ability to sign informed consent, including ≥26 Mini-Mental State Exam.
  • Plasma triglyceride concentration between 130-500 mg/dl.

Exclusion Criteria:

  • Diabetes (plasma glucose: fasting ≥126 mg/dl or ≥200 mg/dl at 2 hr after 75 g glucose load).
  • On diabetes medication or lipid altering agents, including over the counter fish oil/omega 3 fatty acids.
  • Kidney/renal or liver disease.
  • Bleeding disorders or anemia.
  • Endocrine disease.
  • Positive hepatitis or HIV screens.
  • Alcohol abuse or drug abuse
  • Score of <26 on the Mini-Mental State Exam.
  • Allergy to iodine or fish products.
  • Subjects with cerebral aneurysm clips, internal transistorized devices (e.g., neural stimulators), or cardiac pacemakers.
Both
50 Years to 75 Years
Yes
Contact: Leybi L Ramirez, MD.MPH 501)-364-3055 llramirez@uams.edu
Contact: Nick Hurren, PhD (501) 364-3054 Nmhurren@uams.edu
United States
 
NCT01150188
139210, 1R01AG033761-01A1
No
University of Arkansas
University of Arkansas
National Institute on Aging (NIA)
Principal Investigator: Elisabet Borsheim, PhD University of Arkansas
University of Arkansas
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP